Department of Health and Human Services July 2005 – Federal Register Recent Federal Regulation Documents

Results 151 - 200 of 291
Certain Other Dosage Form New Animal Drugs; Oxytetracycline
Document Number: 05-14017
Type: Rule
Date: 2005-07-18
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Pfizer, Inc. The supplemental NADA provides for use of oxytetracycline hydrochloride soluble powder for skeletal marking of finfish fry and fingerlings by immersion.
Privacy Act of 1974; Report of a New System of Records
Document Number: 05-14079
Type: Notice
Date: 2005-07-15
Agency: Centers for Medicare & Medicaid Services, Department of Health and Human Services
In accordance with the requirements of the Privacy Act of 1974, we are proposing to establish a new SOR titled, ``Medicare Retiree Drug Subsidy Program (RDSP), System No. 09-70-0550.'' Under section 1860D-22 of the Social Security Act (the Act), employers and unions who continue to offer prescription drug coverage to their qualifying covered retirees are eligible to receive a tax-free subsidy for allowable drug costs. This amended provision of the Act is mandated by section 101 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) (Pub. L. 108-173). A qualifying covered retiree is a Part D eligible individual who is a participant or the spouse or dependent of a participant; covered under employment-based retiree health coverage that qualifies as a qualified retiree prescription drug plan; and not enrolled in a Part D plan. Employment- Based Retiree Health Coverage is defined as coverage of health care costs under a group health plan based on an individual's status as a retired participant in the plan, or as the spouse or dependent of a retired participant. The term includes coverage provided by voluntary insurance coverage as a result of a statutory or contractual obligation. The Medicare prescription drug benefit and retiree drug subsidy represent additional funding sources that can help employers and unions continue to provide high quality drug coverage for their retirees. The purpose of this system is to collect and maintain information on individuals who are qualifying covered retirees so that accurate and timely subsidy payments may be made to plan sponsors who continue to offer actuarially equivalent prescription drug coverage to the qualifying covered retirees. Information retrieved from this system will also be disclosed to: (1) Support regulatory, reimbursement, and policy functions performed within the agency, or by a contractor or consultant; (2) support constituent requests made to a congressional representative; (3) support litigation involving the agency; and (4) combat fraud and abuse in certain health benefits programs. We have provided background information about the modified system in the ``Supplementary Information'' section below. Although the Privacy Act requires only that CMS provide an opportunity for interested persons to comment on the proposed routine uses, CMS invites comments on all portions of this notice. See ``Effective Dates'' section for comment period.
Oral Dosage Form New Animal Drugs; Lincomycin and Spectinomycin Soluble Powder
Document Number: 05-13975
Type: Rule
Date: 2005-07-15
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by Cross Vetpharm Group Ltd. The ANADA provides for the oral use of lincomycin and spectinomycin soluble powder to create a solution administered in the drinking water of chickens as an aid in the control of airsacculitis.
Draft Guidance for Industry and Food and Drug Administration Staff; The Mammography Quality Standards Act Final Regulations: Modifications and Additions to Policy Guidance Help System #9; Availability
Document Number: 05-13974
Type: Notice
Date: 2005-07-15
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing the availability of the draft guidance entitled ``The Mammography Quality Standards Act Final Regulations: Modifications and Additions to Policy Guidance Help System 9.'' The draft guidance document is intended to assist facilities and their personnel in meeting the Mammography Quality Standards Act (MQSA) final regulations.
Agency Information Collection Activities; Submission for OMB Review; Comment Request; Extension of Existing Information Collection; Certification of Maintenance of Effort Form Title III of the Older Americans Act, Grants for State and Community Program on Aging
Document Number: 05-13938
Type: Notice
Date: 2005-07-15
Agency: Aging Administration, Department of Health and Human Services
The Administration on Aging (AoA) is announcing that the proposed collection of information listed below has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Cooperative Agreements for Tribes and Tribal Organizations for Tobacco Prevention and Control
Document Number: 05-13937
Type: Notice
Date: 2005-07-15
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Fetal Alcohol Syndrome Regional Training Centers
Document Number: 05-13934
Type: Notice
Date: 2005-07-15
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Proposed Information Collection Activity; Comment Request; Proposed Projects
Document Number: 05-13919
Type: Notice
Date: 2005-07-15
Agency: Department of Health and Human Services, Administration for Children and Families, Children and Families Administration
Proposed Information Collection Activity; Comment Request Proposed Project
Document Number: 05-13918
Type: Notice
Date: 2005-07-15
Agency: Department of Health and Human Services, Administration for Children and Families, Children and Families Administration
Medical Devices; Availability of Safety and Effectiveness Summaries for Premarket Approval Applications
Document Number: 05-13901
Type: Notice
Date: 2005-07-15
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is publishing a list of premarket approval applications (PMAs) that have been approved. This list is intended to inform the public of the availability of safety and effectiveness summaries of approved PMAs through the Internet and the agency's Division of Dockets Management.
Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Food Canning Establishment Registration, Process Filing, and Recordkeeping for Acidified Foods and Thermally Processed Low-Acid Foods in Hermetically Sealed Containers
Document Number: 05-13900
Type: Notice
Date: 2005-07-15
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing that a collection of information entitled ``Food Canning Establishment Registration, Process Filing, and Recordkeeping for Acidified Foods and Thermally Processed Low-Acid Foods in Hermetically Sealed Containers'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.
Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; State Petitions for Exemption From Preemption
Document Number: 05-13899
Type: Notice
Date: 2005-07-15
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing that a collection of information entitled ``State Petitions for Exemption From Preemption'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.
Change of Name and Address; Technical Amendment
Document Number: 05-13898
Type: Rule
Date: 2005-07-15
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is amending its regulations to reflect a change in the name and address for the Association of Official Analytical Chemists International (AOAC). This action is editorial in nature and is intended to improve the accuracy of the agency's regulations.
Agency Information Collection Activities: Submission for OMB Review; Comment Request
Document Number: 05-13866
Type: Notice
Date: 2005-07-15
Agency: Centers for Medicare & Medicaid Services, Department of Health and Human Services
Medicare Program; Meeting of the Advisory Panel on Ambulatory Payment Classification (APC) Groups-August 17, 18, and 19, 2005; Correction
Document Number: 05-13965
Type: Notice
Date: 2005-07-14
Agency: Centers for Medicare & Medicaid Services, Department of Health and Human Services
This document corrects technical errors that appeared in the notice published in the Federal Register on July 8, 2005 entitled ``Medicare Program; Meeting of the Advisory Panel on Ambulatory Payment Classification (APC) GroupsAugust 17, 18, and 19, 2005.''
Office of Community Services; CSBG T&TA Promoting Healthy Marriages
Document Number: 05-13893
Type: Notice
Date: 2005-07-14
Agency: Department of Health and Human Services, Administration for Children and Families, Children and Families Administration
The Office of Community Services (OCS) within the Administration for Children and Families (ACF) announces that competing applications will be accepted for a new grant pursuant to the Secretary's authority under section 678(A) of the Community Services Block Grant (CSBG) Act, as amended, by the Community Opportunities, Accountability, and Training and Educational Services (COATES) Human Services Reauthorization Act of 1998 (Pub. L. 105-285). These activities must fund training and technical assistance resources for the Community Services Network to ensure that the needs of eligible entities and programs relating to improving program quality (including quality of financial management practices) are addressed to the maximum extent feasible; and incorporate mechanisms to ensure responsiveness to local needs. The proposed grants will fund training and technical assistance resources for the Community Services Network focusing on improving the quality of programs carried out under the CSBG act and the delivery of healthy marriage strategies among low income people served by local community action agencies. Specifically, OCS will offer one-year grants to fund a one year project period for the creation and dissemination of ``best practice'' technical assistance materials from local community organizations, including those that are faith-based, that have demonstrated success in promoting or sustaining healthy marriages among clients as part of an overall strategy to help low-income people achieve family and child development, and/or self-sufficiency goals. Special emphasis is being placed on the development and dissemination of ``best practice'' materials that focus on a wide range of low-income populations, including racial and ethnic minorities.
2005 White House Conference on Aging
Document Number: 05-13849
Type: Notice
Date: 2005-07-14
Agency: Aging Administration, Department of Health and Human Services
Pursuant to section 10(a) of the Federal Advisory Committee Act as amended (5 U.S.C. Appendix 2), notice is hereby given of the sixth Policy Committee meeting concerning planning for the 2005 White House Conference on Aging. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should inform the contact person listed below in advance of the meeting. This notice is being published less than 15 days prior to the meeting due to scheduling problems.
Diffusion of Partnership for Health to Health Care and Medical Agencies Serving Persons Living With HIV/AIDS
Document Number: 05-13848
Type: Notice
Date: 2005-07-14
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Submission for OMB Review; Comment Request
Document Number: 05-13845
Type: Notice
Date: 2005-07-14
Agency: Department of Health and Human Services, Administration for Children and Families, Children and Families Administration
Decision to Evaluate a Petition To Designate a Class of Employees at the National Bureau of Standards, Van Ness Street, Washington, DC, To Be Included in the Special Exposure Cohort
Document Number: 05-13841
Type: Notice
Date: 2005-07-14
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
The Department of Health and Human Services (HHS) gives notice as required by 42 CFR 83.12(e) of a decision to evaluate a petition to designate a class of employees at the National Bureau of Standards, Van Ness Street, in Washington, DC, to be included in the Special Exposure Cohort under the Energy Employees Occupational Illness Compensation Program Act of 2000. The initial proposed definition for the class being evaluated, subject to revision as warranted by the evaluation, is as follows: Facility: National Bureau of Standards, Van Ness Street. Location: Washington, DC. Job Titles and/or Job Duties: All physicists that worked in the Radioactivity LabEast BuildingBuilding 2. Period of Employment: From 1943 through 1952.
Office of the National Coordinator for Health Information Technolo; ormation of the American Health Information Community
Document Number: 05-13840
Type: Notice
Date: 2005-07-14
Agency: Department of Health and Human Services
This notice announces the establishment of the American Health Information Community (the Community), a committee established under the Federal Advisory Committee Act (Pub. L. No. 92-463, 5 U.S.C., App.) by the Secretary of the Department of Health and Human Services. The American Health Information Community will advise the Secretary and recommend specific actions to achieve a common interoperability framework for health information technology (IT) and serve as a forum for participation from a broad range of stakeholders to provide input on achieving interoperability of health IT. The Community shall not exceed 17 voting members, including the Chair, and members shall be appointed by the Secretary.
Submission of Chemistry, Manufacturing, and Controls Information in a New Drug Application Under the New Pharmaceutical Quality Assessment System; Notice of Pilot Program
Document Number: 05-13829
Type: Notice
Date: 2005-07-14
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is seeking pharmaceutical companies to volunteer to participate in a pilot program involving the submission of chemistry, manufacturing, and controls (CMC) information consistent with the new pharmaceutical quality assessment system. The purpose of the pilot program is twofold. First, the pilot program will provide participating pharmaceutical companies with an opportunity to submit critical CMC information that demonstrates their understanding of quality by design, product knowledge, and process understanding of the drug substance and drug product in a new drug application (NDA). Second, the pilot program will enable the public and regulated industry to provide feedback that will assist FDA in developing a guidance for industry on the new quality assessment system.
Medicare Program; Home Health Prospective Payment System Rate Update for Calendar Year 2006
Document Number: 05-13674
Type: Proposed Rule
Date: 2005-07-14
Agency: Centers for Medicare & Medicaid Services, Department of Health and Human Services
This proposed rule would set forth an update to the 60-day national episode rates and the national per-visit amounts under the Medicare prospective payment system for home health agencies. We are also proposing to implement the revised area labor market Metropolitan Statistical Area designations for calendar year 2006.
National Institutes on Deafness and Other Communication Disorders; Notice of Meeting
Document Number: 05-13826
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings
Document Number: 05-13825
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, National Institutes of Health
National Eye Institute; Notice of Closed Meeting
Document Number: 05-13824
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, National Institutes of Health
Center For Scientific Review; Notice of Closed Meetings
Document Number: 05-13823
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, National Institutes of Health
Center for Scientific Review; Amended Notice of Meeting
Document Number: 05-13822
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, National Institutes of Health
Center for Scientific Review; Amended Notice of Meeting
Document Number: 05-13821
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, National Institutes of Health
Center for Scientific Review; Amended Notice of Meeting
Document Number: 05-13820
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, National Institutes of Health
Center for Scientific Review; Amended Notice of Meeting
Document Number: 05-13819
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed Meeting
Document Number: 05-13818
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, National Institutes of Health
National Cancer Institute; Notice of Closed Meeting
Document Number: 05-13817
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, National Institutes of Health
National Cancer Institute; Notice of Closed Meeting
Document Number: 05-13816
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, National Institutes of Health
National Library of Medicine; Notice of Meeting
Document Number: 05-13815
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of General Medical Sciences; Notice of Closed Meeting
Document Number: 05-13814
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, National Institutes of Health
National Cancer Institute; Notice of Closed Meeting
Document Number: 05-13813
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, National Institutes of Health
National Library of Medicine; Notice of Closed Meetings
Document Number: 05-13812
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, National Institutes of Health
National Center on Minority Health and Health Disparities; Notice of Closed Meetings
Document Number: 05-13811
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Child Health and Human Development; Notice of Closed Meeting
Document Number: 05-13810
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, National Institutes of Health
Center for Scientific Review; Amended Notice of Meeting
Document Number: 05-13809
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, National Institutes of Health
Center for Scientific Review; Amended Notice of Meeting
Document Number: 05-13808
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Document Number: 05-13807
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Child Health and Human Development; Notice of Closed Meeting
Document Number: 05-13806
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, National Institutes of Health
National Library of Medicine: Notice of Meetings
Document Number: 05-13805
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, National Institutes of Health
Prospective Grant of Exclusive License: Mesothelin, a Differentiation Antigen Present on Mesothelium, Mesotheliomas and Ovarian Cancers and Methods and Kits for Targeting
Document Number: 05-13804
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, National Institutes of Health
This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Patent Application No. 60/010,166, filed January 5, 1996, entitled ``Mesothelin, A Differentiation Antigen Present On Mesothelium, Mesotheliomas And Ovarian Cancers And Methods And Kits For Targeting'' [E-002-1996/0-US-01]; United States Patent No. 6,153,430, issued on November 28, 2000, entitled ``Nucleic Acid Encoding Mesothelin, A Differentiation Antigen Present On Mesothelium, Mesotheliomas And Ovarian Cancers'' [E-002-1996/0-US-02]; United States Patent Application No. 09/684,599, filed October 5, 2000, entitled ``Mesothelin, A Differentiation Antigen Present On Mesothelium, Mesotheliomas And Ovarian Cancers And Methods And Kits For Targeting'' (E-002-1996/0-US-03); United States Patent No. 6,083,502, issued on July 4, 2000, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002-1996/1-US-02]; PCT Application No. PCT/US97/ 00224, filed January 3, 1997, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002-1996/1-PCT-01]; Australian Patent No. 703769, filed January 3, 1997, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002-1996/1-AU-03]; Canadian Patent No. 2241604, filed January 3, 1997, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002- 1996/1-CA-04]; Japanese Patent Application No. 9-525355, filed January 3, 1997, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002-1996/1-JP-06]; European Patent No. 0871492, filed January 3, 1997, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002-1996/1-EP-05]; Switzerland Patent Application No. 0871492, filed January 3, 1997, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002-1996/1-CH-07]; German Patent No. 69726404.1, filed January 3, 1997, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' (E-002-1996/1-DE-08); French Patent Application No. 0871492, filed January 3, 1997, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002- 1996/1-FR-09]; Italian Patent No. 05503/BE/2004, January 3, 1997, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002-1996/1T-10]; Spanish Patent No. 0871492, filed January 3, 1997, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002-1996/1-ES-11]; United Kingdom Patent No. 0871492, filed January 3, 1997, entitled ``Mesothelium Antigen And Methods And Kits For Targeting It'' [E-002-1996/1-GB-12]; United States Patent No. 5,320,956, issued June 14, 1996, entitled ``Monoclonal Antibody'' [E-195-1990/0-US-20]; United States Patent No. 5,525,337, issued June 11, 1996, entitled ``Monoclonal Antibody Binding Cell Surface Antigen For Diagnosing Cancer'' [E-195-1990/0-US-21]; United States Patent No. 5,817,313, issued October 6, 1998, entitled ``Monoclonal Antibodies And Conjugates Thereof Useful For The Treatment Of Cancer'' [E-195-1990/0-US-22]; PCT Patent Application No. PCT/US91/ 07227, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195- 1990/0-PCT-02]; Denmark Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-DK-03]; United Kingdom Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-GB-04]; Austrian Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-AT-05]; Belgium Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-BE-06]; European Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E- 195-1990/0-EP-09]; French Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-FR-11]; German Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-DE-08]; Greece Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-GR-12]; Netherlands Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-NL-15]; Italian Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-IT-13]; Luxembourg Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-LU-14]; Spanish Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E- 195-1990/0-ES-10]; Sweden Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-SE-16]; Switzerland Patent No. 0554356, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-CH-07]; Australian Patent No. 648363, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-AU-17]; Canadian Patent No. 2093928, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E-195-1990/0-CA-18]; and Japanese Patent No. 2660241, filed October 9, 1991, entitled ``Monoclonal Antibody'' [E- 195-1990/0-JP-19] to Morphotek, Inc., which has offices in Exton, Pennsylvania. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory may be worldwide, and the field of use may be limited to the use of licensee's MORAb-009 antibody for the treatment of mesothelin-expressing cancer.
Notice of Correction to Availability of Funds for the Projects To Establish Public Assistance Reporting Information System (PARIS) State Partnership Grants
Document Number: 05-13773
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, Administration for Children and Families, Children and Families Administration
This notice is to inform interested parties of changes made to the Funding Opportunity for Projects to Establish Public Assistance Reporting Information System (PARIS) State Partnership Grants published on Monday, April 25, 2005, with a due date for applications of June 24, 2005, which is now extended until August 8, 2005. 1. The following changes are made to Section I, ``Funding Opportunity Description'': a. There will be separate grants awarded to each Member and Partner State, such that a Member State will no longer have fiduciary responsibility for its Partner State [page 21222]; b. The following paragraph is struck: ``After evaluation of all grant applications, and if chosen for an award, the Member state will be awarded a grant under which it will act as a fiduciary agent to the Partner state. The Member state will be responsible for all funding that is provided to its Partner state and will reimburse funding provided hereunder, as costs are incurred, for specific items delineated in its approved grant application budget and in accordance with HHS fiscal and grants management requirements.'' [page 21222] and replaced with: ``Separate applications for a partnership agreement must be submitted by both the Member State and the Partner State with separate budget requests. An application from a Partner State must identify its Member State and an application from a Member State must identify its Partner State. As costs are incurred for specific items delineated in the approved grant application budgets, States must adhere to HHS fiscal and grants management requirements.''; c. The phrase ``Member State'' is struck and replaced with ``State'' in the paragraph that reads: ``This list is meant to be illustrative, not exhaustive of the type of issues the Member state should address when preparing the application.'' [page 21222]; 2. The following changes are made to Section I, ``Funding Opportunity Description,'' under the ``parameters'' list [page 21222]: a. In the first sentence in paragraph (3), the phrase ``the Member State'' is replaced with ``each applicant'' so that the sentence reads, ``Each applicant must provide a proposed budget that includes the resources and associated costs it believes are necessary to participate in the match process.'' The second sentence is revised to read: ``The proposed budgets will be evaluated for adequacy, reasonableness, and to ensure that implementation of the partnership will be both operationally effective and successful''; b. The language in paragraph (5) is struck and replaced with: ``For Member States to be eligible for this funding opportunity they must have participated in at least two of the last six PARIS matches from (February 2004 through May 2005)''; c. The language in paragraph (6) is struck and replaced with: ``Applicants are cautioned that the ceiling for each grant award is $200,000 for a Partner State and $100,000 for a Member State. Applications exceeding the $200,000/$100,000 threshold will be considered non-responsive and will not be eligible for funding under this announcement''; d. The first sentence in paragraph (7) is struck and replaced with: ``Two applications must be submitted for each identified partnership One from a Member State and one from a Partner State.''; e. The language in paragraph (8) is struck and replaced with: ``The Partner State must enroll in the PARIS Project and provide a copy of the PARIS agreement to ACF prior to the grant award issuance in order to document the Partner State's consent to the project. The following link shows the PARIS Agreement: https://www.acf.hhs.gov/nhsitrc/paris/ agreepar.html ''; f. The language in paragraph (10) is struck and replaced with: ``Besides the Interstate and Veterans matches, States are encouraged to participate in any additional matches available, such as the Federal match.''; 3. The following changes are made to Section II, ``Award Information'': The ``Ceiling on the Amount of Individual Awards Per Project Period'' and the ``Average Projected Award Amount Per Project Period'' are revised as follows: ``$200,000 for a Partner State and $100,000 for a Member State'' [page 21223]; 4. The following changes are made to Section III.1, ``Eligibility Information, Additional Information on Eligibility'' [page 21223]: a. The first sentence is struck and replaced with, ``In the context of this grant announcement, eligible applicants include both Member States of PARIS and proposed Partner States as defined in Section I, ``Funding Opportunity Description.'' To be considered an eligible Member State, the State must have participated in at least two of the last six quarterly matches from February 2004 through May 2005.''; b. The sentence reading: ``The following States meet this eligibility factor'' now includes Oregon in the list of eligible Member States; c. The sentence that reads ``* * * and only these Member States may submit applications under this grant'' is struck and replaced with ``only these eligible Member States may qualify to submit applications under this grant announcement as Member States defined in this grant announcement.''; d. The sentence reading, ``The application must include the Partnership agreement as well as the appropriate signed PARIS agreement for the Partner State,'' is struck and replaced with: ``The application need only identify the other State in the Partnership in lieu of attaching the actual agreement; however, a signed PARIS agreement and Partnership agreement must both be provided to ACF prior to the grant award issuance.'' 5. The following changes are made to Section III (3), ``Eligibility Information, Other, Disqualification Factors'' [page 21223]: a. The sentence stating, ``Applications that are not submitted by a Member state,'' is struck and replaced with: ``Applications that are not submitted by a State.'' ; b. The following sentence is struck: ``Applications that fail to include a written Partnership agreement between the Member state and Partner state.''; c. The following sentence is struck: ``Applications that fail to provide a signed PARIS agreement by the Partner state.''; d. In the sentence that reads, ``Applications that fail to specify at least two of the last six quarterly PARIS matches from November 2003 through February 2005 in which the Member state has participated,'' the dates are struck and replaced with ``February 2004'' and ``May 2005'' respectively. 6. The following changes are made to IV.2, ``Application and Submission Information, Content and Form of Application Submission'': a. The sentence, ``Applications must contain a partnership agreement from the Partner State indicating its agreement to team with the Member State for purposes of this grant'' is struck and replaced with: ``Applications should identify what other State, be they a Member State or a Partner State, they are teaming with. The teaming or partnership agreement must be submitted to ACF prior to grant award issuance.'' [page 21223]; b. The sentence, ``Note that the application requires proof of an agreement between the PARIS Member State and its Partner State as well as a signed PARIS agreement (available on the PARIS website)'' is struck and replaced with: ``The proof of agreement between the PARIS Member State and its Partner State, as well as a signed PARIS agreement (available on the PARIS website), must both be submitted to ACF prior to grant award issuance.'' [page 21224]; 7. The following changes are made to Section IV. 3, ``Submission Dates and Times, Due Date for Applications'': The due date for applications is extended from June 24, 2005 to August 8, 2005. [page 21224]; 8. The following changes are made to Section IV.3, the ``Checklist'': Under the ``When to Submit'' column, the language for the PARIS Agreement and Partnership Agreement is replaced with, ``By date of award.'' [page 21225]; 9. The following changes are made to Section V, ``Application Review Information, Evaluation Criteria'' [page 21228]: a. The paragraph under the criterion ``Approach'' is struck and replaced with: ``Applications will be evaluated in terms of the extent to which they include a plan that (1) reflects the understanding of the characteristics, needs and services that are available from the PARIS Project and the potential for a Partnership agreement achieving the provision of services that directly address the fulfillment of the PARIS Project; (2) is appropriate and feasible; (3) can be reliably evaluated; (4) if successfully implemented, can be sustained after Federal funding has ceased.''; b. The point value for the criterion ``Budget and Budget Justification'' is revised from 10 points to 15 points; c. The entire criterion ``Third-Party Agreements'' worth 5 points is struck. 10. The second full paragraph in Section V(2), ``Review and Selection Process'' is revised to read: ``If an insufficient number of acceptable applications, as determined by ACF, are received under this program announcement ACF has the option of negotiating and awarding grant amounts higher than the $200,000 award ceiling for Partner States and $100,000 award ceiling for Member States, set forth in this announcement among those applicants who have submitted acceptable applications.''
Memorandum of Understanding Between the Food and Drug Administration and the Food and Drug Administration Alumni Association, Inc.
Document Number: 05-13765
Type: Notice
Date: 2005-07-13
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is providing notice of a memorandum of understanding (MOU) between the Food and Drug Administration and the Food and Drug Administration Alumni Association, Inc., (FDAAA). FDA and FDAAA agree to partner on future specific undertakings that are considered beneficial to both organizations, are directly related to the mission of FDA, and are within FDA's statutory authorities.
Submission for OMB Review, Comment Request; State- and Local-Level Questionnaire for Project on Collection of Marriage and Divorce Statistics at the National, State and Local Levels
Document Number: 05-13736
Type: Notice
Date: 2005-07-13
Agency: Department of Health and Human Services, Administration for Children and Families, Children and Families Administration
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.